SCHEMBL2401910

SCHEMBL2401910

O=C(NCCc1ccc(Cl)cc1)C1=NOC2(CCN(S(=O)(=O)c3cccs3)CC2)C1

nearest known ligand 0.59

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 9/20 0.59
GAA P10253 3/20 0.52
MAPT P10636 3/20 0.52
RAB9A P51151 2/20 0.45
NPC1 O15118 1/20 0.45
SMN1; SMN2 Q16637 1/20 0.45
TP53 P04637 1/20 0.45
HTT P42858 1/20 0.44
CCR1 P32246 2/20 0.44
SLC6A9 P48067 1/20 0.43
MAPK1 P28482 1/20 0.43
MEN1 O00255 1/20 0.42
KMT2A Q03164 1/20 0.42
PKM P14618 1/20 0.42
TSHR P16473 1/20 0.42
NPSR1 Q6W5P4 1/20 0.42
POLB P06746 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6411124 0.86 ALDH1A1 (0.56) ALDH1A1GAAMAPTRAB9ATP53
SCHEMBL2401811 0.83 MAPT (0.50) ALDH1A1GAAMAPTRAB9ASMN1; SMN2
SCHEMBL2401314 0.81 NPSR1 (0.43) ALDH1A1MAPTRAB9ANPC1HTT
SCHEMBL2400969 0.80 ALDH1A1 (0.58) ALDH1A1GAAMAPTSMN1; SMN2TP53
SCHEMBL2402499 0.79 ALDH1A1 (0.55) ALDH1A1MAPTRAB9ASMN1; SMN2TP53
SCHEMBL2405235 0.79 KMT2A (0.55) ALDH1A1GAAMAPTRAB9ANPC1
SCHEMBL2403146 0.76 CYP2C19 (0.43) ALDH1A1GAAMAPTRAB9ASMN1; SMN2
SCHEMBL2402059 0.76 RAB9A (0.44) ALDH1A1GAAMAPTRAB9ANPC1
SCHEMBL2403567 0.75 DRD4 (0.55)
SCHEMBL2400331 0.75 KDM4E (0.54) ALDH1A1SMN1; SMN2TP53MAPK1PKM

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20110224172-A1 Substituted 1-Oxa-2,8-Diaza-Spiro [4,5] Dec-2-Ene Derivatives and Related Treatment Methods GRUENENTHAL GMBH (DE) 2011-09-15 US claimed
US-8048890-B2 Analgesics; neuropathic pain; headaches; muscle relaxants; incontence; tinnitus; diarrhea; antiarrhythmia agents; antiischemic agents; antiinflammatory agents; antiulcer agents; antidepressants; antiepileptic agents GRUENENTHAL GMBH (DE) 2011-11-01 US disclosed
US-20110224172-A1 Substituted 1-Oxa-2,8-Diaza-Spiro [4,5] Dec-2-Ene Derivatives and Related Treatment Methods GRUENENTHAL GMBH (DE) 2011-09-15 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110224172-A1 Substituted 1-Oxa-2,8-Diaza-Spiro [4,5] Dec-2-Ene Derivatives and Related Treatment Methods SULT1E1, DECR1, CYP8B1 ALDH1A1 156/4885GAA 1186/4885MAPT 3594/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.